Monitor upcoming clinical data readouts for MP0712 and MP0317 in 2026 as key catalysts. The shortened cash runway to late 2027 suggests potential need for additional financing or partnership milestones. Watch for updates on the isotope-agnostic strategy and new target nominations in H2 2026.
Price Chart
Executive Summary
Molecular Partners reported Q1 2026 results showing a net loss of CHF 13.1M, improved from a CHF 16.8M loss in Q1 2025, with no revenue from collaborations. Cash and short-term time deposits totaled CHF 79M (~$100M), providing runway into late 2027 (previously early 2028). The company initiated two clinical studies (MP0712 Phase 1/2a and MP0317 Phase 2) and presented positive preclinical data on its Switch-DARPin platform, but the shortened cash runway and lack of revenue are notable concerns for a pre-commercial biotech.
Key Facts
- Net loss of CHF 13.1M in Q1 2026 vs CHF 16.8M in Q1 2025 (improvement of 22%)
- No revenue from research collaborations in Q1 2026 or Q1 2025
- Cash and short-term time deposits of CHF 79M (~$100M) as of March 31, 2026
- Cash runway shortened to late 2027 from previously expected early 2028
- Operating expenses decreased to CHF 13.4M from CHF 16.1M YoY
- MP0712 Phase 1/2a trial initiated with 4 clinical sites open, initial data expected in 2026
- MP0317 Phase 2 investigator-initiated trial started for cholangiocarcinoma
- Shareholders' equity decreased to CHF 68.5M from CHF 80.3M at year-end 2025
- Basic and diluted net loss per share improved to CHF 0.35 from CHF 0.45 YoY
Financial Impact
Net loss improved by CHF 3.6M YoY; cash burn of CHF 18.4M in Q1 2026; cash runway shortened by ~6 months to late 2027
Risk Factors
- Cash runway shortened to late 2027, may require dilutive financing
- No revenue from collaborations, fully dependent on cash reserves
- Clinical-stage biotech with no approved products
- Potential for negative clinical trial results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001745114-26-000019 |
| Document: prforq12026sec.htm | 0001745114-26-000019 |
| Document: molecularpartners-form6xk_.htm | 0001745114-26-000019 |
| Document: 0001745114-26-000019-index-headers.html | 0001745114-26-000019 |
| Document: 0001745114-26-000019-index.html | 0001745114-26-000019 |
| Document: 0001745114-26-000019.txt | 0001745114-26-000019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 8w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.59 (−18.04%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.59 (−10.25%) |
Jul 16, 2026 14w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.59 (−12.44%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.59 (−10.25%) |
Jul 2, 2026 16w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.59 (−9.80%) |
Jul 2, 2026 16w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.59 (−9.80%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.59 (−9.11%) |
May 12, 2026 23w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.59 (−10.25%) |
May 1, 2026 25w ago | Press Release | $4.24 $3.95 | ▼ −6.84% | ▼ −12.12% | $3.59 (−15.33%) |
Mar 30, 2026 30w ago | 6-K | $3.93 $4.28 | ▲ +8.91% | ▼ −3.69% | $3.59 (−8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers